skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
With the launch of Regeneron/Sanofi’s first-in-class PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, Praluent, in July 2015 and the following launch of Amgen’s PCSK9 inhibitor, Repatha, shortly after, the treatment of dyslipidaemia has once again been thrust into the limelight, with efficacy and cost of novel treatment at the forefront of discussion

Download Your Dyslipidemia Whitepaper today

This analysis will discuss the current landscape of dyslipidaemia drugs from preclinical to preregistration phases of development, focussing primarily on the alternatives to the PCSK9 inhibitors

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: